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CC BY-NC-ND license (http://creativeInvasive aspergillosis is a life-threatening infectious complication in immunocompromised pa-
tients, especially with malignancy, and in some cases, it causes extensive tissue destruction
and subsequent systemic illness, leading to multiorgan failure and death. Skin involvement
and amphotericin B resistance are very rare findings of aspergillosis. Herein, we report the
case of a primary hemophagocytic syndrome patient who developed subcutaneous nodules
in the 3rd month of bone marrow transplantation from which Aspergillus fumigatus was culti-
vated despite the fact that she was under antifungal therapy. In immunocompromised patients
with prolonged fever, atypical presentations of invasive mycosis should be kept in mind, and
early appropriate therapy should be initiated promptly to decrease morbidity and mortality.
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Figure 1 (A) Axial thorax CT image shows multiple sub-
pleural and parenchymal millimetric nodules surrounded by
mild ground-glass opacities (halo sign) in the upper and lower
lobes of bilateral lungs (arrows). (B) Axial T1-weighted MR
image of the brain obtained after the injection of contrast
material shows multiple ring-enhancing lesions at the cortico-
medullary junction in the hemisphere, consistent with the
abscess. CT Z computed tomography; MR Z magnetic
resonance.
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In patients affected by hematological diseases, fungal in-
fections, especially those caused by Aspergillus spp. or by
other filamentous fungi, are being increasingly diagnosed.
Data from the Centers for Disease Control and Preven-
tion reveal that the mortality associated with invasive
aspergillosis has increased by 357% since 1980.1 The mor-
tality of untreated invasive respiratory aspergillosis is
nearly 100%; however, the survival among patients treated
with amphotericin B is nearly 34%,2,3 and it was found to be
48.6% with voriconazole in a recent study.4 Incidence of
invasive aspergillosis ranges from 0.5% to 30% according to
series.2,5,6
We report a case with primary hemophagocytic syn-
drome who had subcutaneous nodules during the 3rd month
of bone marrow transplantation from which Aspergillus
fumigatus was cultivated despite the fact that she was
under antifungal therapy.
2. Case Report
A 16-year-old girl who had been diagnosed as primary
hemophagocytic syndrome, treated with steroid, etopo-
side, and intravenous immunoglobulin in her two consec-
utive attacks (at 9 and 12 years) was hospitalized for bone
marrow transplantation (BMT) from a fully matched donor
(her sister). In the protocol of BMT preparation, busulfan,
cyclophosphamide, etoposide, and steroid were initiated.
As she had respiratory distress, hypoxia, cough, and
bilateral pericardiac infiltration in chest X-ray (CXR), 1 day
before BMT, imipenem, vancomycin, clarithromycin, and
liposomal amphotericin B (3 mg/kg/day) were initiated.
On the day of BMT, she had hemoptysis; thorax computed
tomography (CT) yielded results consistent with pulmonary
hemorrhage or infection. On the 2nd day of hospitalization,
chest X-ray (CXR) showed right pleural effusion, thor-
acentesis results showed transudate criteria; additionally,
she had acute renal impairment and needed hemodialysis,
and also her respiratory distress increased; hence, she was
intubated. Neutrophil engraftment occurred on Day 14
after BMT. After she had been mechanically ventilated for
23 days, she was extubated. After 2 days of extubation,
she had extensive mucositis; paranasal CT showed maxil-
lary, frontal, and sphenoidal sinusitis with soft tissue
density, which was consistent with fungal infection. Tho-
rax CT demonstrated multiple nodules surrounded by mild
ground-glass opacities (halo sign) in the upper and lower
lobes of bilateral lungs, which were not seen in previous
CT (Figure 1A). Under therapy, new lesions were present;
therefore, caspofungin was added to amphotericin B.
When antifungal therapy was initiated, galactomannan
(GM) antigen (GM levels were studied using the sandwich
The enzyme-linked immunosorbent assay (ELISA) com-
mercial kit [Platelia Aspergillus; Bio-Rad Laboratories,
France] in accordance with the manufacturer’s instruc-
tion), OD indices were 0.14 (0-1: negative, 1-1.5: board),
but when caspofungin was started, the GM level has risen
to 1.04. On Day 61 after BMT, CT results showed regression
of soft tissue densities filling the sinus, but hemorrhagic
and painful nodular cutaneous lesions of different sizes
Figure 2 Subcutaneous nodule on the upper extremity.
Systemic aspergillosis: Skin involvement and amphotericin B resistance in an adolescent 345appeared on bilateral extremities (Figure 2). Thorax CT
showed the regression of lung nodules but revealed pleural
effusion bilaterally and subcutaneous nodules on the chest
wall.
As she experienced sudden vision loss for a short period,
cranial magnetic resonance imaging (MRI) was studied,
which yielded cerebral and cerebellar multiple cortico-
medullary abscesses of which the largest had a diameter of
1.5 cm (Figure 1B). The biopsy of one of the nodular lesions
of skin showed infiltration of dermis and subcutaneous fat
by inflammatory cells, necrosis, and microabscess forma-
tion. Clusters of narrow-angle-branching and septate fungal
hyphae consistent with Aspergillus were noticed in periodic
acideSchiff (PAS) and Gomori methenamine silver stains
(Figure 3). Immunohistochemistry showed positive staining
with the aspergillus antibody. Culture from biopsy yielded
Aspergillus fumigatus [susceptibility testing and minimum
inhibitory concentration (MIC) criteria for fluconazole,
voriconazole, and caspofungin was performed according toFigure 3 PAS staining showed clusters of septate and
narrow-angle-branching fungal hyphae. PAS Z periodic
acideSchiff.the Clinical and Laboratory Standards Institute (CLSI) M38-
A2guide]. Broth microdilution susceptibility testing was
performed. MIC results were as follows: amphotericin B,
4 mg/mL; voriconazole, 0.06 mg/mL; and caspofungin,
0.03 mg/mL. After the addition of voriconazole, instead of
caspofungin (6 mg/kg every 12 hours after loading dose) to
liposomal amphotericin B, cutaneous lesions disappeared
and thorax and paranasal CT confirmed there was regres-
sion of the lesions.3. Discussion
Although extensive information about pulmonary aspergil-
losis in immunocompromised patients is available, cuta-
neous aspergillosis occurs relatively infrequently.
Therefore, it remains poorly described, especially among
bone marrow transplant recipients, mainly because litera-
ture reports have focused on the more frequent and severe
clinical scenario of pulmonary or disseminated infection. In
previous reports, cutaneous aspergillosis has been
described as either a primary or secondary infection. Pri-
mary cutaneous aspergillosis usually involves sites of skin at
or near intravenous access catheter sites, traumatic inoc-
ulation, and at sites associated with occlusive dressings,
burns, or surgery. Secondary cutaneous lesions result either
from contiguous extension to the skin from infected un-
derlying structures or from widespread blood-borne seeding
of the skin.7 Findlay et al8 attempted to distinguish five
appearances of disseminated aspergillosis: solitary necro-
tizing dermal plaque, subcutaneous granuloma or abscess,
persistent eruptive dermal maculopapules, transient ery-
thema and generalized rash, and as an entity in immuno-
competent hosts, progressive confluent granuloma. The
morphology of the breakthrough skin lesion in our patient
fits that of subcutaneous abscess in dermis.
The differential diagnosis includes candidemia, which is
present with red pinpoint maculae in approximately 10% of
patients9 and fusariosis metastatically involving the skin in
the majority of cases. Fusarial lesions might present as
subcutaneous nodules.10 Cryptococcal and nocardial dis-
ease were considered in the light of simultaneous pulmo-
nary and skin lesions. We would like to underline the
importance of an aggressive diagnostic approach whenever
tender nodules of the skin occur in the immunocompro-
mised host as in our patient. The prompt initiation of an
appropriate therapy is also the second most important step
to increase the patient survival rate.
Another important point of our case other than cuta-
neous involvement is amphotericin B resistance of Asper-
gillus, which was rarely reported in literature.1113
Breakthrough fungal infection under amphotericin B ther-
apy is uncommon. Therefore, our patient with a cutaneous
lesion is an important example. Among 196 cases of A.
fumigatus infections in Japan, isolates with MICs of 2 mg/
mL were reported for 1.0% of the isolates (2/196).11 In a
study from Greece, amphotericin B resistance was reported
as 10.8%,12 and high levels of MIC for amphotericin B (>1
mg/mL) were also reported by Mortensen et al13 r as 2.7%.
Resistance to amphotericin B in our patient might have
caused the breakthrough infection.
346 A. Ozkaya-Parlakay et alClinical findings of aspergillosis in immunocompromised
patients with hematological malignancies may be more
different than classical findings. Although skin involvement
is estimated because of Candida or Fusarium infection, this
case emphasizes that Aspergillus may also be encountered
with dermal lesions and that urgent diagnostic approaches
are necessary. As antifungal resistance of A. fumigatus
(especially to azoles) is one of the concerns in the treat-
ment of aspergillosis, the possibility of resistance to
amphotericin B should be kept in mind in cases that are
unresponsive to therapy, similar to our case.References
1. Steinbach WJ. Pediatric aspergillosis disease and treatment
differences in children. Pediatr Infect Dis J 2005;24:358e64.
2. Denning DW, Marinus A, Cohen J, Spence D, Herbrecht R,
Pagano L, et al. An EORTC multicentre prospective survey of
invasive aspergillosis in haematological patients: diagnosis and
therapeutic outcome. J Infect 1998;37:173e80.
3. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate:
systematic review of the literature. Clin Infect Dis 2001;32:
358e66.
4. Jacobs F, Selleslag D, Aoun M, Sonet A, Gadisseur A. An
observational efficacy and safety analysis of the treatment of
acute invasive aspergillosis using voriconazole. Eur J Clin
Microbiol Infect Dis 2012;31:1173e9.
5. Wright JA, Bradfield SM, Park JR, Hawkins DS. Prolonged sur-
vival after invasive aspergillosis: a single-institution review of
11 cases. J Pediatr Hematol Oncol 2003;25:286e91.6. Groll AH, Kurz M, Schneider W, Witt V, Schmidt H, Schneider M,
et al. Five-year survey of invasive aspergillosis in a paediatric
cancer centre. Epidemiology, management and long-term
survival. Mycoses 1999;42:431e42.
7. van Burik JA, Colven R, Spach DH. Cutaneous aspergillosis. J
Clin Microbiol 1998;36:3115e21.
8. Findlay GH, Roux HF, Simson IW. Skin manifestations in
disseminated aspergillosis. Br J Dermatol 1971;85:94e7.
9. Viscoli C, Girmenia C, Marinus A, Collette L, Martino P,
Vandercam B, et al. Candidemia in cancer patients: a pro-
spective, multicenter surveillance study by the Invasive Fungal
Infection Group (IFIG) of the European Organization for
Research and Treatment of Cancer (EORTC). Clin Infect Dis
1999;28:1071e9.
10. Boutati EI, Anaissie EJ. Fusarium, a significant emerging
pathogen in patients with hematologic malignancy: ten years’
experience at a cancer center and implications for manage-
ment. Blood 1997;90:999e1008.
11. Tashiro M, Izumikawa K, Minematsu A, Hirano K, Iwanaga N,
Ide S, et al. Antifungal susceptibilities of Aspergillus fumigatus
clinical isolates obtained in Nagasaki, Japan. Antimicrob
Agents Chemother 2012;56:584e7.
12. Arabatzis M, Kambouris M, Kyprianou M, Chrysaki A,
Foustoukou M, Kanellopoulou M, et al. Polyphasic identification
and susceptibility to seven antifungals of 102 Aspergillus iso-
lates recovered from immunocompromised hosts in Greece.
Antimicrob Agents Chemother 2011;55:3025e30.
13. Mortensen KL, Johansen HK, Fuursted K, Knudsen JD, Gahrn-
Hansen B, Jensen RH, et al. A prospective survey of Aspergillus
spp. in respiratory tract samples: Prevalence, clinical impact
and antifungal susceptibility. Eur J Clin Microbiol Infect Dis
2011;30:1355e63.
